DE69024809D1 - Herpes simplex virus typ 1 mutante - Google Patents
Herpes simplex virus typ 1 mutanteInfo
- Publication number
- DE69024809D1 DE69024809D1 DE69024809T DE69024809T DE69024809D1 DE 69024809 D1 DE69024809 D1 DE 69024809D1 DE 69024809 T DE69024809 T DE 69024809T DE 69024809 T DE69024809 T DE 69024809T DE 69024809 D1 DE69024809 D1 DE 69024809D1
- Authority
- DE
- Germany
- Prior art keywords
- gene
- hsv
- base pairs
- therapeutic gene
- vivo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898918616A GB8918616D0 (en) | 1989-08-15 | 1989-08-15 | Herpes simplex virus type 1 mutant |
PCT/GB1990/001276 WO1991002788A1 (en) | 1989-08-15 | 1990-08-14 | Herpes simplex virus type 1 mutant |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69024809D1 true DE69024809D1 (de) | 1996-02-22 |
DE69024809T2 DE69024809T2 (de) | 1996-05-30 |
Family
ID=10661668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69024809T Expired - Fee Related DE69024809T2 (de) | 1989-08-15 | 1990-08-14 | Herpes simplex virus typ 1 mutante |
Country Status (12)
Country | Link |
---|---|
US (1) | US5837532A (de) |
EP (1) | EP0487611B1 (de) |
JP (1) | JP3000482B2 (de) |
AT (1) | ATE132897T1 (de) |
AU (1) | AU628650B2 (de) |
CA (1) | CA2067330C (de) |
DE (1) | DE69024809T2 (de) |
DK (1) | DK0487611T3 (de) |
ES (1) | ES2084703T3 (de) |
GB (2) | GB8918616D0 (de) |
WO (1) | WO1991002788A1 (de) |
ZA (1) | ZA906401B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610287B1 (en) | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
US5849572A (en) * | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5688936A (en) * | 1992-06-11 | 1997-11-18 | The Regents Of The University Of California | Vesicle membrane transport proteins |
AU692423B2 (en) * | 1992-09-25 | 1998-06-11 | Institut National De La Sante Et De La Recherche Medicale | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US5763217A (en) * | 1993-11-10 | 1998-06-09 | University Of British Columbia | Method of using, process of preparing and composition comprising recombinant herpesvirus vectors |
GB9415319D0 (en) * | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
CA2234877A1 (en) * | 1995-10-19 | 1997-04-24 | St. Jude Children's Research Hospital | Herpesvirus vectors and their uses |
GB9615794D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
DE69823482T2 (de) * | 1997-02-14 | 2005-04-14 | Binney & Smith Inc. | Waschbare farbzusammensetzung |
US5981626A (en) * | 1997-02-14 | 1999-11-09 | Binney & Smith Inc. | Washable coloring composition suitable for use in dry erase markers |
US5900094A (en) * | 1997-02-14 | 1999-05-04 | Binney & Smith Inc. | Image transfer method for use with water based dry erase markers |
GB9807865D0 (en) * | 1998-04-09 | 1998-06-10 | Univ London | Herpes simplex virus latency associated transcript polypeptides |
AU2002307749A1 (en) * | 2001-05-09 | 2002-11-25 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
WO2005080581A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Florida Research Foundation, Inc. | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression |
EP2377882A1 (de) | 2004-10-28 | 2011-10-19 | University of Pittsburgh of the Commonwealth System of Higher Education | Peripher verabreichte Gentherapie mit Glutaminsäure-Decarboxylase gegen Schmerzen aufgrund einer Rückenmarksverletzung |
US7825231B2 (en) | 2005-06-01 | 2010-11-02 | Darren P. Wolfe | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
US20060275812A1 (en) * | 2005-06-01 | 2006-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Assay for agonists and antagonists of ion channels and for regulators of genetic expression |
US8865185B2 (en) * | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
EP2059255A4 (de) * | 2006-09-08 | 2011-08-31 | Univ Pennsylvania | Hsv-1- und hsv-2-impfstoffe sowie verfahren zu ihrer anwendung |
EP2114449B1 (de) * | 2006-12-28 | 2016-02-17 | The Trustees of the University of Pennsylvania | Kombinierte herpes simplex virus subunit-impfstoffe und anwendungsverfahren |
US20080289058A1 (en) * | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
TW201823463A (zh) | 2010-03-23 | 2018-07-01 | 美商英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
EP3450568A3 (de) | 2011-03-04 | 2019-04-24 | Intrexon Corporation | Vektoren für bedingte proteinexpression |
US10046064B2 (en) | 2014-09-07 | 2018-08-14 | Selecta Biosciences, Inc. | Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
DK3408382T3 (da) | 2016-01-27 | 2022-06-20 | Oncorus Inc | Onkolytiske virale vektorer og anvendelser deraf |
WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
EP3504335A4 (de) | 2016-08-23 | 2020-04-15 | Bluebird Bio, Inc. | Tim3-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung |
KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
WO2018075541A1 (en) | 2016-10-17 | 2018-04-26 | Bluebird Bio, Inc. | TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE |
JP7263235B2 (ja) | 2016-11-17 | 2023-04-24 | 2セブンティ バイオ インコーポレイテッド | TGFβシグナルコンバーター |
KR20240015743A (ko) | 2017-01-07 | 2024-02-05 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
AU2018221730B2 (en) | 2017-02-15 | 2024-06-20 | 2Seventy Bio, Inc. | Donor repair templates multiplex genome editing |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
MX2019014100A (es) | 2017-05-25 | 2020-02-07 | Bluebird Bio Inc | Variantes de endonucleasas cblb, composiciones y metodos de uso. |
RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
EP4400174A2 (de) | 2017-09-01 | 2024-07-17 | The Francis Crick Institute Limited | Immunregulierende moleküle und deren verwendungen |
WO2019070974A1 (en) | 2017-10-04 | 2019-04-11 | Bluebird Bio, Inc. | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
BR112020007157A2 (pt) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
US11638749B2 (en) | 2017-10-17 | 2023-05-02 | International Aids Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
CN112384204B (zh) | 2018-02-26 | 2023-03-14 | 安托瑞斯公司 | 致耐受性脂质体及其使用方法 |
AU2019287720A1 (en) | 2018-06-14 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | CD79A chimeric antigen receptors |
WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
WO2020185298A1 (en) * | 2019-03-14 | 2020-09-17 | Massachusetts Institute Of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
JP2022534741A (ja) | 2019-05-28 | 2022-08-03 | セレクタ バイオサイエンシーズ インコーポレーテッド | 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物 |
CN114765990A (zh) | 2019-10-10 | 2022-07-19 | 昂克诺斯公司 | 双重病毒和双重溶瘤病毒以及治疗方法 |
WO2021207636A2 (en) | 2020-04-10 | 2021-10-14 | Sola Biosciences Llc | Compositions and methods for the treatment of protein aggregation disorders |
JP2023524414A (ja) | 2020-04-28 | 2023-06-12 | ソラ・バイオサイエンシズ・エルエルシー | Tdp-43プロテイノパチーの処置のための組成物および方法 |
WO2021248038A1 (en) | 2020-06-05 | 2021-12-09 | Sola Biosciences Llc | Compositions and methods for the treatment of synucleinopathies |
EP4162036A1 (de) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Lösliche enpp1- oder enpp3-proteine und verwendungen davon |
CN111635913B (zh) * | 2020-06-16 | 2022-03-04 | 广东东阳光药业有限公司 | 构建体及其应用 |
US20240025954A1 (en) | 2020-10-26 | 2024-01-25 | Sola Biosciences Llc | Compositions and Methods for the Treatment of Alzheimer's Disease |
CN117980326A (zh) | 2021-07-14 | 2024-05-03 | 2赛文缇生物公司 | 与来自抗体的结合结构域融合的经工程化的t细胞受体 |
WO2023060221A2 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of proteopathies |
WO2023060248A1 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282721C (en) * | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
JPH02502605A (ja) * | 1987-03-13 | 1990-08-23 | シェリング・コーポレーション | 遺伝子発現の刺激方法 |
WO1990009441A1 (en) * | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
CA2039921A1 (en) * | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
-
1989
- 1989-08-15 GB GB898918616A patent/GB8918616D0/en active Pending
-
1990
- 1990-08-13 ZA ZA906401A patent/ZA906401B/xx unknown
- 1990-08-14 DE DE69024809T patent/DE69024809T2/de not_active Expired - Fee Related
- 1990-08-14 CA CA002067330A patent/CA2067330C/en not_active Expired - Fee Related
- 1990-08-14 WO PCT/GB1990/001276 patent/WO1991002788A1/en active IP Right Grant
- 1990-08-14 AT AT90913020T patent/ATE132897T1/de not_active IP Right Cessation
- 1990-08-14 DK DK90913020.5T patent/DK0487611T3/da active
- 1990-08-14 ES ES90913020T patent/ES2084703T3/es not_active Expired - Lifetime
- 1990-08-14 EP EP90913020A patent/EP0487611B1/de not_active Expired - Lifetime
- 1990-08-14 GB GB9017767A patent/GB2234972B/en not_active Revoked
- 1990-08-14 JP JP2511813A patent/JP3000482B2/ja not_active Expired - Fee Related
- 1990-08-14 AU AU62762/90A patent/AU628650B2/en not_active Ceased
-
1995
- 1995-05-05 US US08/435,280 patent/US5837532A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU628650B2 (en) | 1992-09-17 |
DE69024809T2 (de) | 1996-05-30 |
ES2084703T3 (es) | 1996-05-16 |
US5837532A (en) | 1998-11-17 |
CA2067330A1 (en) | 1991-02-16 |
ATE132897T1 (de) | 1996-01-15 |
JPH05505302A (ja) | 1993-08-12 |
GB8918616D0 (en) | 1989-09-27 |
EP0487611A1 (de) | 1992-06-03 |
EP0487611B1 (de) | 1996-01-10 |
GB2234972B (en) | 1993-08-04 |
AU6276290A (en) | 1991-04-03 |
GB9017767D0 (en) | 1990-09-26 |
JP3000482B2 (ja) | 2000-01-17 |
WO1991002788A1 (en) | 1991-03-07 |
ZA906401B (en) | 1991-06-26 |
CA2067330C (en) | 2005-05-10 |
GB2234972A (en) | 1991-02-20 |
DK0487611T3 (da) | 1996-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE132897T1 (de) | Herpes simplex virus typ 1 mutante | |
Smith et al. | Antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. | |
Quinn et al. | DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein | |
Caradonna et al. | Induction of uracil-DNA glycosylase and dUTP nucleotidohydrolase activity in herpes simplex virus-infected human cells. | |
Morgan et al. | Identification of the DNA sequences encoding the large subunit of the mRNA-capping enzyme of vaccinia virus | |
ATE141517T1 (de) | Gen-sequenzentransfer und -exprimierung bei zellen des zentralen nervensystems mit mutierenden herpes-simplex-viren, die deletionen in viren-replikationsgenen enthalten | |
Protić et al. | Enhancement of DNA repair capacity of mammalian cells by carcinogen treatment | |
CA2011654A1 (en) | Recombinant poxvirus host range selection system | |
AUPN477695A0 (en) | Gene therapy | |
ATE73348T1 (de) | Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung. | |
Spang et al. | Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein | |
Nass | Modified nucleosides and cancer | |
Deb et al. | A 67-base-pair segment from the Ori-S region of herpes simplex virus type 1 encodes origin function | |
Keller et al. | Role of the human cytomegalovirus major immediate-early promoter's 19-base-pair-repeat cyclic AMP-response element in acutely infected cells | |
JPWO2020081568A5 (de) | ||
EP0326127A3 (de) | Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung | |
HALL et al. | Structural organization and unusual codon usage in the DNA polymerase gene from herpes simplex virus type 1 | |
Cole et al. | Biological properties of simian virus 40 host range mutants lacking the COOH-terminus of large T antigen | |
Rabkin et al. | Initiation of DNA replication at cloned origins of bacteriophage T7 | |
Aurelian | Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase | |
GB2359083A (en) | Mutant herpes simplex viruses and uses thereof | |
ATE164885T1 (de) | Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten | |
BR9912719A (pt) | Processo para propagar um vìrus do herpes mutante, uso de uma linhagem de célula, linhagem de célula, vìrus, e, composição farmacêutica | |
ATE190658T1 (de) | Virale nucleotidsequenzen | |
Pedrali-Noy et al. | Evidence of a repetitive sequence in vaccinia virus DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: BTG INTERNATIONAL LTD., LONDON, GB |
|
8339 | Ceased/non-payment of the annual fee |